浆细胞疾病中的生化骨标志物
本文综述了骨转换标志物(BTMs)在浆细胞疾病(包括多发性骨髓瘤、意义未明的单克隆丙种球蛋白病和冒烟型骨髓瘤)中的临床相关性。骨形成标志物反映成骨细胞活性,骨吸收标志物反映破骨细胞活性,部分BTMs与疾病负荷和进展相关,但其常规临床应用受生物学变异、肾功能损害和检测标准化缺乏的限制。随着骨髓瘤治疗演变,需进一步研究明确BTMs与影像学和临床风险模型联合应用的角色。
要点
- 骨转换标志物可非侵入性评估骨代谢,潜在用于疾病监测、预后判断和风险分层。
- 骨形成标志物(如骨特异性碱性磷酸酶、I型前胶原N端前肽)反映成骨细胞活性。
- 骨吸收标志物(如羧基端胶原交联、脱氧吡啶啉)反映破骨细胞活性。
核心结论
- 部分骨转换标志物与浆细胞疾病的疾病负荷和进展相关,但常规临床应用受限。
研究设计与样本
- 综述,探讨骨转换标志物在浆细胞疾病(包括多发性骨髓瘤、意义未明的单克隆丙种球蛋白病和冒烟型骨髓瘤)中的临床相关性。
主要发现
- 骨形成标志物如骨特异性碱性磷酸酶和I型前胶原N端前肽反映成骨细胞活性。
- 骨吸收标志物如羧基端胶原交联和脱氧吡啶啉反映破骨细胞活性。
- 部分骨转换标志物与疾病负荷和进展相关。
临床怎么用
- 骨转换标志物可作为非侵入性手段评估骨代谢,潜在用于疾病监测、预后判断和风险分层。
- 骨转换标志物潜在用于评估骨髓瘤和骨质疏松治疗的反应。
- 常规使用需考虑生物学变异、肾功能损害和检测标准化缺乏的限制。
局限性
- 骨转换标志物的常规临床应用受生物学变异限制。
- 肾功能损害影响骨转换标志物的解读。
- 骨转换标志物检测缺乏标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a haematological malignancy characterised by clonal plasma cell accumulation in the bone marrow, frequently resulting in myeloma bone disease. Disruption of bone homeostasis, driven by increased osteoclastic resorption and suppressed osteoblastic formation, leads to osteolytic lesions and skeletal-related events, contributing substantially to morbidity and mortality. Bone turnover markers (BTMs) provide a non-invasive means of assessing bone metabolism, with potential applications in disease monitoring, prognostication, risk stratification from monoclonal gammopathy of undetermined significance (MGUS) to MM and evaluation of response to myeloma and osteoporosis therapies. This review examines the clinical relevance of BTMs in plasma cell dyscrasias, including MM, MGUS and smouldering MM. Bone formation markers, such as bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide, reflect osteoblastic activity, while resorption markers, including carboxy-terminal collagen crosslinks and deoxypyridinoline, indicate osteoclastic activity. Although several BTMs correlate with disease burden and progression, their routine clinical use is limited by biological variability, renal impairment and lack of assay standardisation. As myeloma therapies continue to evolve, further research is needed to define the role of BTMs alongside imaging and clinical risk models to optimise bone disease management.
引用
- Nador G, Vijjhalwar R, Javaid MK, et al. Biochemical bone biomarkers in plasma cell dyscrasias. Br J Haematol. 2026. PMID: 41948808. doi:10.1111/bjh.70467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。